Osteoporosis Update From the 2010 Santa Fe Bone Symposium

Lewiecki, E. Michael; Bilezikian, John P.; Khosla, Sundeep; Marcus, Robert; McClung, Michael R.; Miller, Paul D.; Watts, Nelson B.; Maricic, Michael

doi:10.1016/j.jocd.2010.12.001

Next »Journal of Clinical Densitometry
Volume 14, Issue 1 , Pages 1-21, January 2011

Osteoporosis Update From the 2010 Santa Fe Bone Symposium

E. Michael Lewiecki
- New Mexico Clinical Research & Osteoporosis Center, Albuquerque, NM, USA
- Address correspondence to: E. Michael Lewiecki, MD, FACP, FACE, New Mexico Clinical Research & Osteoporosis Center, 300 Oak St. NE, Albuquerque, NM 87106.
John P. Bilezikian
- Department of Medicine, Columbia University College of Physicians and Surgeons, New York City, NY, USA
Sundeep Khosla
- College of Medicine, Mayo Clinic, Rochester, MN, USA
Robert Marcus
- Stanford University School of Medicine, Stanford, CA, USA
Michael R. McClung
- Oregon Osteoporosis Center, Portland, OR, USA
Paul D. Miller
- Colorado Center for Bone Research, Lakewood, CO, USA
Nelson B. Watts
- University of Cincinnati College of Medicine, Cincinnati, OH, USA
Michael Maricic
- Catalina Pointe Rheumatology, Tucson, AZ, USA

Received 1 December 2010; received in revised form 6 December 2010; accepted 6 December 2010.

Abstract

The 11th Santa Fe Bone Symposium was held in Santa Fe, NM, USA, on August 6–7, 2010. This annual event addresses clinically relevant advances in the fields of osteoporosis and metabolic bone disease. The venue includes plenary presentations by internationally recognized experts, oral presentations of abstracts, and interactive panel discussions of challenging cases and controversial issues. Attendees are active participants throughout the symposium program. Topics for the 2010 symposium included potential applications of novel technologies for the assessment of skeletal health for research and clinical practice; new and emerging treatments for osteoporosis; appropriate use of pharmacological agents to prevent osteoporosis; controversies with bisphosphonate therapy; practical applications of the World Health Organization fracture risk assessment tool (FRAX; World Health Organization Collaborating Centre for Metabolic Bone Diseases, University of Sheffield, UK); insights into the use of osteoanabolic agents to enhance fracture healing; and challenges in laboratory testing in the assessment of factors contributing to skeletal fragility. Concurrent sessions focused on critical thinking for technologists in the acquisition and analysis of data with dual-energy X-ray absorptiometry. The key messages from each presentation, including the best available medical evidence and potential current and future clinical applications, are provided here.

Key Words: Bisphosphonate, denosumab, emerging, fracture, osteoporosis